Linagliptin
Back to searchMolecule Structure
Scientific Name
Linagliptin
Description of the Drug
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08882
http://www.drugbank.ca/drugs/DB08882
Brand Name(s)
Tradjenta, Trajenta
Company Owner(s)
Boehringer Ingelheim, Boehringer Ingelheim Pharmaceuticals Inc, Sunshine Lake Pharma Co Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dipeptidyl peptidase IV | SINGLE PROTEIN | INHIBITOR | CHEMBL284 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL160188 | ||||
| DrugBank | DB08882 | ||||
| PubChem: Thomson Pharma | 15083733 | ||||
| PubChem | 10096344 | ||||
| LINCS | LSM-45916 | ||||
| Nikkaji | J2.712.937D | ||||
| PDBe | 356 | ||||
| BindingDB | 50228403 | ||||
| DrugCentral | 4175 | ||||
| Brenda | 75287 | 6288 | 26657 | 138963 | 18424 |
| ChemicalBook | CB71518518 | ||||
| Guide to Pharmacology | 6318 | ||||
| rxnorm | TRADJENTA | LINAGLIPTIN | |||
| PubChem: Drugs of the Future | 56310616 | ||||
| ChEBI | 68610 | ||||
| ZINC | ZINC000003820029 |
